Atosiban Adverse Events: What Studies Report

What Atosiban Is and Where It Is Approved

Atosiban is a prescription oxytocin receptor antagonist. A 2001 review in Journal de Gynecologie, Obstetrique et Biologie de la Reproduction described atosiban as an oxytocin receptor antagonist developed for tocolysis, meaning suppression of uterine contractions in preterm labour (PMID 11397999). A 2011 review of oxytocin antagonists for the management of preterm birth described the class, its receptor target and the clinical trial record that had accumulated for atosiban by that time (PMID 21170825).

Atosiban holds marketing authorisation in the European Union and several other jurisdictions for delaying imminent preterm birth within defined gestational age limits. There is no atosiban product approved by the United States Food and Drug Administration, so no United States prescribing information exists. Any use of atosiban outside an approved indication, including the investigational uses discussed further down this page, is investigational. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, symptom or pregnancy related decision, and talk to your prescriber rather than relying on a summary page.

Boxed Warning Status

Approved European labeling for atosiban containing products does not use the United States style boxed warning format, and because no FDA approved atosiban product exists, no United States boxed warning has ever been issued for this drug. The absence of a boxed warning is a regulatory and formatting fact about labeling in the jurisdictions where the product is authorised. It is not a statement about how any individual pregnancy, contraindication or adverse reaction should be weighed, and the authoritative text remains the current approved labeling held by the dispensing pharmacy and the prescribing clinician.

Contraindications and Warnings Listed in Labeling

Approved labeling for atosiban restricts use in a series of obstetric situations where continuing a pregnancy may be judged hazardous or where the drug has not been studied. Labeling categories include the following.

• Gestational age outside the authorised window, which excludes very early and late preterm presentations.
• Premature rupture of the membranes beyond the gestational age limit stated in labeling.
• Abnormal fetal heart rate patterns, suspected intrauterine growth restriction and intrauterine fetal death.
• Antepartum haemorrhage settings such as suspected placental abruption and placenta praevia requiring delivery.
• Eclampsia and severe pre-eclampsia requiring delivery, and suspected intrauterine infection.
• Known hypersensitivity to the active substance or excipients.

Labeling also advises monitoring of blood loss after delivery because of the drug's action on uterine oxytocin receptors, notes limited data in multiple pregnancy and in hepatic or renal impairment, and notes that treatment should take place where obstetric monitoring is available. These label items are summarised here in general terms; frequency categories and the full wording differ between national labels and between manufacturers.

Maternal Cardiovascular Events: What Studies Report

A 2017 study published in The Journal of Maternal-Fetal and Neonatal Medicine examined how oxytocin and atosiban modulated heart rate in pregnant women, and the researchers reported on heart rate measures taken during exposure to each agent (PMID 27030149). Comparative work has focused on how an oxytocin receptor antagonist differs from older tocolytics that act on beta adrenergic receptors or calcium channels. A 2010 review in International Journal of Women's Health compared atosiban with nifedipine for the management of preterm labour and reported that maternal adverse effect profiles differed between the two drugs (PMID 21072306). A 2015 review asking whether any tocolytic works in acute preterm labour compared agents including atosiban and reported differences in maternal tolerability alongside differences in effect on delivery timing (PMID 24990666).

Pulmonary oedema is a complication described in the tocolysis literature more broadly. A 2014 case report in Case Reports in Critical Care described acute pulmonary oedema occurring during nicardipine tocolysis and characterised it as a rare but severe complication of that calcium channel blocker (PMID 25215245). That report concerned a different drug and is included here only as context for why comparative tolerability is discussed in tocolysis reviews.

Gastrointestinal, Neurological and General Symptoms: What Studies Report

Approved labeling for atosiban lists nausea as the most frequently recorded adverse reaction, with vomiting, headache, dizziness, hot flushes, tachycardia and hypotension also appearing in the adverse reaction table, along with injection site reaction and hyperglycaemia. Labeling groups these items into frequency categories that vary slightly between national texts. Published reviews that summarised the atosiban trial programme described this adverse reaction pattern as the basis for comparisons with betamimetic tocolytics (PMID 21170825), and a 2018 critical analysis of evidence based data on acute tocolysis in Geburtshilfe und Frauenheilkunde reviewed how the available agents compared on both effect and reported adverse events (PMID 30655648).

Summary table of reported categories

Fetal, Neonatal and Trial Level Outcomes: What Studies Report

The largest recent placebo controlled evidence came from APOSTEL 8, a multicentre randomised controlled trial published in The Lancet in 2025 that compared atosiban with placebo in women with threatened preterm birth and reported perinatal outcomes for the randomised groups (PMID 40049187). A placebo controlled design of that kind allows maternal and neonatal events recorded during the trial to be compared against a placebo group rather than against historical experience, and the trial publication is the primary source for how those events were distributed.

Earlier syntheses had already noted that tocolytic trials differ widely in which neonatal endpoints they capture. The 2015 review of tocolysis for acute preterm labour reported that effects on delivery delay did not always translate into measured neonatal benefit across the agents it examined (PMID 24990666), and the 2018 evidence based analysis of acute tocolysis reached similar questions about endpoint selection across the tocolytic literature (PMID 30655648).

Investigational Uses and Their Reported Adverse Events: What Studies Report

Several studied uses of atosiban sit outside approved labeling and are investigational. Maintenance tocolysis, meaning continued tocolytic treatment after contractions have been arrested, was examined in a 2005 article in BJOG that reviewed whether prolonging tocolytic treatment after the acute episode changed outcomes (PMID 15715609). Uterine relaxation before external cephalic version is another investigational setting; a 2007 study in Acta Obstetricia et Gynecologica Scandinavica reported on the use of atosiban and ritodrine for external cephalic version and compared the two agents in that procedure (PMID 17653876). Adverse event profiles recorded in investigational settings are not interchangeable with the adverse reaction table in approved labeling, because the populations, exposure durations and monitoring differ.

Preclinical and Mechanistic Research: What Studies Report

Animal and mechanistic work helps explain why oxytocin receptor blockade is studied at all, and it occasionally raises signals that have not been examined in people. A 2016 study in Toxicology Letters reported that oxytocin was involved in the proconvulsant effects of sildenafil in a rodent model and implicated CREB signalling, with an oxytocin receptor antagonist used as a pharmacological tool in that work (PMID 27220266). A 2026 paper in Nature Communications described the discovery of an antagonist nanobody targeting the oxytocin receptor and reported a tocolytic effect in mice, positioning the molecule against existing oxytocin receptor antagonists (PMID 42864336). Rodent findings do not establish human adverse reactions and are reported here as background on the receptor target rather than as safety information for people.

Limitations of the Published Evidence

• Adverse reaction tables in labeling reflect pooled trial data from the registration programme, not population wide surveillance, and frequency categories differ between national labels.
• Comparative reviews such as the 2010 nifedipine comparison (PMID 21072306) drew on trials with differing entry criteria, so adverse event rates are not directly transferable between studies.
• Placebo controlled data arrived late relative to approval, with APOSTEL 8 reporting randomised comparisons against placebo in 2025 (PMID 40049187).
• Investigational settings such as external cephalic version involve short exposures in different populations (PMID 17653876).

Where Questions Belong

Atosiban is administered in hospital settings under obstetric supervision in the countries where it is approved. Decisions about whether a tocolytic is appropriate, what the contraindications mean in an individual pregnancy, and how any symptom experienced during or after treatment should be interpreted are clinical matters. Anyone with a question about a symptom, a label warning or a reported adverse event should raise it with the prescribing clinician or the treating obstetric team, who hold the current labeling and the clinical record.

References

• Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial (Lancet, 2025)
• Oxytocin antagonists for the management of preterm birth: a review (American Journal of Perinatology, 2011)
• Tocolysis. Atosiban, an oxytocin receptor antagonist (Journal de Gynecologie, Obstetrique et Biologie de la Reproduction, 2001)
• The effects of oxytocin and atosiban on the modulation of heart rate in pregnant women (Journal of Maternal-Fetal and Neonatal Medicine, 2017)
• Management of preterm labor: atosiban or nifedipine? (International Journal of Women's Health, 2010)
• Tocolysis for acute preterm labor: does anything work (Journal of Maternal-Fetal and Neonatal Medicine, 2015)
• Acute Tocolysis: a Critical Analysis of Evidence-Based Data (Geburtshilfe und Frauenheilkunde, 2018)
• Maintenance tocolysis (BJOG, 2005)
• The use of atosiban and ritodrine in external cephalic version (Acta Obstetricia et Gynecologica Scandinavica, 2007)
• Nicardipine-induced acute pulmonary edema: a rare but severe complication of tocolysis (Case Reports in Critical Care, 2014)
• Oxytocin is involved in the proconvulsant effects of Sildenafil: Possible role of CREB (Toxicology Letters, 2016)
• Discovery of an antagonist nanobody targeting the oxytocin receptor with tocolytic effect in mice (Nature Communications, 2026)